Santarus, Inc. (NASDAQ:SNTS)

CAPS Rating: 2 out of 5

A pharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by gastroenterologists or primary care physicians.

Recs

0
Player Avatar murph74124 (40.22) Submitted: 4/6/2007 11:01:55 AM : Outperform Start Price: $7.50 SNTS Score: -16.68

addresses $billin market; secondary benefits re acid reflux;big co-marketing deals;faster PPI response;undiscovered by analysts

Featured Broker Partners


Advertisement